ArticleFrontiers in pharmacology2025
A multifaceted microenvironment nanoregulator for targeted ovarian cancer therapy.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Engineering Plant-Derived Exosome-like Nanoparticles as Bioinspired Nanocarriers: From Physicochemical Properties to Tumor Delivery Performance.Biomedicines · 2026Review
- Green nanomedicine for cancer therapy.Chinese medical journal · 2026Review
- Plant-derived extracellular vesicles for drug delivery: current and future.Regenerative biomaterials · 2026Review
- Small Extracellular Vesicles: Unraveling Their Roles in Ovarian Cancer Progression and Tapping Into Clinical Application Potential.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of ovarian cancer is hindered by its insidious onset and rapid progression. Exosomes (EXOs) present a promising therapeutic strategy for ovarian cancer by modulating the tumor microenvironment. However, concerns regarding the biosafety of animal-derived EXOs pose significant challenges to the development of innovative formulations. In this study, we propose a universal strategy to engineer plant-derived EXOs as microenvironment nanoregulators for targeted ovarian cancer therapy. EXOs derived from ginger were purified, loaded with the natural bioactive compound curcumin (Cur) with high encapsulation efficiency, and functionalized with a tumor-targeting aptamer. Upon intravenous administration, the resulting multifaceted microenvironment nanoregulator, termed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.